GLUTAMATE DYNAMICS AND CLINICAL OUTCOME IN EARLY SCHIZOPHRENIA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 与谷氨酸的具体研究及其对大脑成像和神经心理参数的假设影响相关的是一种假设，即成像和神经心理测量在澄清精神诊断和预后方面是有用的。在将这一研究项目转化为临床领域时，将分析来自大脑成像和神经心理学的数据，以评估这些措施的有效性，以帮助确定诊断。此外，一些研究发现，脑部成像测量与药物反应有关。因此，影像和神经心理测试将与随访中的症状结果相关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Related to the specific study of glutamate and its hypothesized impact on brain imaging and neuropsychological parameters is the hypothesis that imaging and neuropsychological measures can be useful in clarifying psychiatric diagnosis and prognosis. In translating this research project to the clinical arena, the data from brain imaging and neuropsychology will be analyzed to assess the utility of these measures to assist in diagnositic certainty. In addition, some studies have found that brain imaging measures are related to medication response. Therefore, imaging and neuropsychological testing will be correlated with symptomatic outcome at follow-up visits.